{"denoms":[{"counts":[{"groupId":"BG000","value":"113"},{"groupId":"BG001","value":"112"},{"groupId":"BG002","value":"295"},{"groupId":"BG003","value":"293"},{"groupId":"BG004","value":"813"}],"units":"Participants"}],"groups":[{"description":"COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"(dMMR Cohort): Arm 1: Active Comparator (Placebo, Paclitaxel, Carboplatin)"},{"description":"COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.","id":"BG001","title":"(dMMR Cohort): Arm 2: Experimental (Pembrolizumab, Paclitaxel, Carboplatin)"},{"description":"COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.","id":"BG002","title":"(pMMR Cohort): Arm 1: Active Comparator (Placebo, Paclitaxel, Carboplatin)"},{"description":"COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.","id":"BG003","title":"(pMMR Cohort): Arm 2: Experimental (Pembrolizumab, Paclitaxel, Carboplatin)"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"37","upperLimit":"85","value":"66"},{"groupId":"BG001","lowerLimit":"38","upperLimit":"81","value":"67"},{"groupId":"BG002","lowerLimit":"29","upperLimit":"90","value":"65"},{"groupId":"BG003","lowerLimit":"31","upperLimit":"93","value":"66"},{"groupId":"BG004","lowerLimit":"29","upperLimit":"93","value":"66"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"113"},{"groupId":"BG001","value":"112"},{"groupId":"BG002","value":"295"},{"groupId":"BG003","value":"293"},{"groupId":"BG004","value":"813"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"48"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"273"},{"groupId":"BG003","value":"263"},{"groupId":"BG004","value":"741"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"24"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"6"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"17"},{"groupId":"BG004","value":"38"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"4"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"51"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"116"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"86"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"212"},{"groupId":"BG003","value":"212"},{"groupId":"BG004","value":"602"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"45"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"Randomized population (with definitive MMR status)"}